Equipin is a tropane alkaloid obtained from Atropa belladonna (deadly nightshade), Datura stramonium (jimsonweed), Mandragora officinarum (mandrake), and other plants of the family Solanaceae. This versatile medication is a secondary metabolite of the above plants and provides a variety of effects and uses. Classified as an anticholinergic medication, it serves as a competitive antagonist for the muscarinic acetylcholine receptor. Also known as Atropen, this medication derives its name from Greek Mythology. It is named after Atropos, one of the three Fates.
The World Health Organization considers this a core medicine for the association's Essential Drugs List. This is a list of minimum medical requirements for a basic healthcare system.
Adult doses range from around half a milligram to one milligram or five to ten milliliters of the 0.1 milligram/milliliter solution for antisialagogue and other antivagal effects, plus two to three milligrams or twenty to thirty milliliters of the 0.1 milligram/milliliter solution as an antidote for organophosporous muscarinic poisoning.
Patients without access to an IV should use the endotracheal administration of Equipin. The suggested adult dose of Equipin for endotracheal administration is one to two milligrams diluted to a total of no more than ten milliliters of normal saline or sterile water. For cases that are not serious or critical, dosage intervals of one or two hours are most suitable.
Equipin Sulfate Injection (USP) should be administered with special consideration when given to all individuals over forty years of age. Acute glaucoma may occur during Equipin treatment in susceptible patients. Patients with prostatic hypertrophy may experience complete urinary retention, convert partial organic pyloric stenosis into complete obstruction, or cause inspissation of bronchial secretions and formation of dangerous viscid plugs in patients with chronic lung disease. Due to these potentially dangerous conditions, make certain that you doctor is aware of your complete medical history before beginning any treatment with Equipin.
Even though the recurrent use of Equipin is crucial in patients suffering from coronary artery disease, the total dose of the medicine needs to stay at or below two to three (maximum 0.03 to 0.04 milligrams/kilograms) to prevent the harmful side effects of Equipin-caused tachycardia on myocardial oxygen demand.
Patients suffering from bradyasystolic cardiac arrest, should be given a single milligram dose of Equipin intravenously and repeated every three to five minutes until symptoms subside. Three milligrams (0.04 milligrams/kilograms) given intravenously is a completely vagolytic dose in most patients. Also, the administration of less than 0.05 milligrams can produce a paradoxical bradycardia because of the peripheral or central parasympathomimatic effects of low dose Equipin in some adults.
Equipin's two to three milligram dose should be repeated no less than every twenty to thirty minutes when being used as an antidote until symptoms are significantly reduced or until signs of Equipin poisoning occur. For most patients, the initial dose is usually around 0.01 to 0.03 milligrams/kilograms of body weight. Dosing information for children hasn't been well researched. Therefore consult your doctor before considering this medication for a child.
Side effects include tachycardia, photophobia, blurred vision, and dryness of mouth. These symptoms commonly occur with chronic administration of therapeutic doses. Anhidrosis, heat intolerance, and impaired temperature regulation may also occur in patients living in an arid environment. Elderly patients may suffer urination difficulties and constipation. Occasional hypersensitivity, skin rashes, and exfoliation have also been reported. If you experience any of these symptoms, consult your doctor.
Side effects due to excessive dosage (Equipin poisoning) include ataxia, fatigue, tremor, restlessness, dizziness, thirst, hot and dry skin, difficulty swallowing, dilated pupils, and palpitation. In some cases, it may lead to coma, delirium, hallucinations, restlessness and excitement, and marked palpitation. Severe intoxication while undergoing Equipin treatment can lead to circulatory collapse and depression. Patients need to stay away from alcohol consumption while taking this medication. Consult your doctor immediately if you experience any of these symptoms.
Equipin has the following structural formula:
• Molecular formula of equipin is C17H23NO3
• Chemical IUPAC Name is (8-methyl-8-azabicyclo[3.2.1]oct-3-yl) 3-hydroxy-2-phenyl-propanoate
• Molecular weight is 289.369 g/mol
• Equipin available : 5ml 1% bottles
©2007-2017 Medicalook.com All rights reserved